Department Pathophysiology, School of Medicine, University of Warmia and Mazury, 10-082 Olsztyn, Poland.
Department of Gynecology and Obstetrics, School of Medicine, Collegium Medicum University of Warmia and Mazury, 10-561 Olsztyn, Poland.
Int J Mol Sci. 2020 Nov 26;21(23):8988. doi: 10.3390/ijms21238988.
Cancer is now the second leading cause of death worldwide. It is estimated that every year, approximately 9.6 million people die of oncologic diseases. The most common origins of malignancy are the lungs, breasts, and colorectum. Even though in recent years, many new drugs and therapeutic options have been introduced, there are still no safe, effective chemopreventive agents. Cyclitols seem poised to improve this situation. There is a body of evidence that suggests that their supplementation can decrease the incidence of colorectal cancer, lower the risk of metastasis occurrence, lower the proliferation index, induce apoptosis in malignant cells, enhance natural killer (NK) cell activity, protect cells from free radical damage, and induce positive molecular changes, as well as reduce the side effects of anticancer treatments such as chemotherapy or surgery. Cyclitol supplementation appears to be both safe and well-tolerated. This review focuses on presenting, in a comprehensive way, the currently available knowledge regarding the use of cyclitols in the treatment of different malignancies, particularly in lung, breast, colorectal, and prostate cancers.
癌症是全球范围内的第二大死亡原因。据估计,每年约有 960 万人死于肿瘤疾病。恶性肿瘤最常见的起源部位是肺部、乳房和结肠直肠。尽管近年来已经引入了许多新的药物和治疗选择,但仍然没有安全有效的化学预防药物。环己醇类似乎有望改善这种情况。有大量证据表明,它们的补充可以降低结直肠癌的发病率,降低转移发生的风险,降低增殖指数,诱导恶性细胞凋亡,增强自然杀伤 (NK) 细胞活性,保护细胞免受自由基损伤,并诱导阳性分子变化,以及减少化疗或手术等抗癌治疗的副作用。环己醇类补充剂似乎既安全又耐受良好。这篇综述重点全面介绍了目前关于环己醇类在治疗不同恶性肿瘤(特别是肺癌、乳腺癌、结直肠癌和前列腺癌)中的应用的相关知识。